​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $245.88, with a high of $300.00 and a low of $175.00. This represents a 16.68% increase from the last price of $210.73.

$150 $180 $210 $240 $270 $300 High: $300 Avg: $245.88 Low: $175 Last Closed Price: $210.73

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (63.27%), 17 Hold (34.69%), 1 Sell (2.04%), and 0 Strong Sell (0.00%).

Buy
Total 49 1 17 31 Strong Sell Sell Hold Buy Strong Buy

BIIB Price Target Upside V Benchmarks

TypeNameUpside
StockBiogen16.68%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks9.63%

Price Target Trends

1M3M12M
# Anlaysts51957
Avg Price Target$244.40$237.58$215.65
Last Closing Price$210.73$210.73$210.73
Upside/Downside15.98%12.74%2.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26320111-35
Aug, 26320121-36
Jul, 26318141-36
Jun, 26218151-36
May, 26317161-37
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Paul MatteisStifel Nicolaus$242.00$214.7712.68%14.84%
Sep 10, 2026HSBC$175.00$210.73-16.96%-16.96%
Sep 03, 2026Piper Sandler$245.00$222.6710.03%16.26%
Aug 25, 2026RBC Capital$260.00$218.1219.20%23.38%
Aug 13, 2026Wolfe Research$300.00$208.8743.63%42.36%
Jul 30, 2026Terence FlynnMorgan Stanley$231.00$206.5011.86%9.62%
Jul 30, 2026H.C. Wainwright$251.00$205.7422.00%19.11%
Jul 30, 2026RBC Capital$240.00$204.1017.59%13.89%
Jul 30, 2026UBS$240.00$204.6217.29%13.89%
Jul 30, 2026Canaccord Genuity$248.00$209.2318.53%17.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026HSBCReduceReducehold
Sep 03, 2026Piper SandlerOverweightOverweighthold
Aug 25, 2026RBC CapitalOutperformOutperformhold
Aug 18, 2026Wolfe ResearchOutperformOutperforminitialise
Aug 13, 2026Wolfe ResearchOutperformupgrade
Aug 03, 2026CitigroupNeutralNeutralhold
Jul 30, 2026H.C. WainwrightBuyBuyhold
Jul 30, 2026UBSBuyBuyhold
Jul 29, 2026OppenheimerOutperformOutperformhold
Jul 21, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$5 $10 $15 $20 $25 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.44$20.97$8.02$11.20$8.85---
Avg Forecast$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Low Forecast$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Surprise %-45.60%22.56%-46.50%-31.79%-46.30%---

Revenue Forecast

$9B $9B $10B $10B $11B $12B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.98B$10.17B$9.84B$9.68B$9.81B---
Avg Forecast$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Low Forecast$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Surprise %1.01%1.00%-0.93%0.43%4.04%---

Net Income Forecast

$500M $1B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.56B$3.05B$1.16B$1.63B$1.29B---
Avg Forecast$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Low Forecast$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Surprise %13.84%67.40%--32.69%-48.48%---

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 17 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 49 Wall Street analysts, averages $245.88 over the next 12 months. The price target range spans from $175 at the low end to $300 at the high end, suggesting a potential 16.68% change from the previous closing price of $210.73.

How does Biogen stock forecast compare to its benchmarks?

Biogen's stock forecast shows a 16.68% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (9.63%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • September 2026: 8.57% Strong Buy, 57.14% Buy, 31.43% Hold, 2.86% Sell, 0% Strong Sell.
  • August 2026: 8.33% Strong Buy, 55.56% Buy, 33.33% Hold, 2.78% Sell, 0% Strong Sell.
  • July 2026: 8.33% Strong Buy, 50.00% Buy, 38.89% Hold, 2.78% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December 2026 is $17.37, marking a 96.27% increase from the reported $8.85 in 2025. Estimates for the following years are $18.95 in 2027, and $20.72 in 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December 2026 is $9.56B, reflecting a -2.51% decrease from the reported $9.81B in 2025. The forecast for 2027 is $9.92B, and $10.14B for 2028.

What is Biogen’s net income forecast?

Biogen's net income forecast for the fiscal year ending in December 2026 stands at $2.37B, representing an 83.24% increase from the reported $1.29B in 2025. Projections indicate $2.56B in 2027, and $3.02B in 2028.